Targeted Intraoperative Radiotherapy (TARGIT) with INTRABEAM

Delivery of targeted, intraoperative radiation therapy (TARGIT) with INTRABEAM® is a treatment option for early stage breast cancer care.This risk-adapted therapeutic solution expands treatment options for a select patient cohort. 

Study verifies effectiveness of the TARGIT

The results of a multinational, randomized clinical study (TARGIT-A) of 3,451 patients at 33 centers in 10 countries confirms the intraoperative targeted radiotherapy (TARGIT) with INTRABEAM is non-inferior to traditional external beam radiotherapy (EBRT) for early stage breast cancer.1 A subject group with a favorable risk profile (median age 63 years, median tumor size 13 mm, 83% pN0, 91% estrogen receptor positive) was treated.2

TARGIT-A Immediate IORT Delivery Cohort

Both study groups in the TARGIT-A study showed good tolerance of the radiotherapy. The percent within each study group in the TARGIT-A study that have not had a recurrence after 5 years of treatment is shown in the group below. 

1 Vaidya JS, Wenz F, Bulsara M, et al. Targeted intraoperative radiotherapy for early breast cancer: TARGIT-A trial-updated analysis of local recurrence and first analysis of survival Abstract S 4-2, published in: CancerRes; 72 (24 Suppl.) December 15, 2012

2 Vaidya JS, Joseph DJ, Tobias JS et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet 2010; 376: 91-102

WEB.5380

We use cookies on this site. Cookies are small text files that are stored on your computer by websites. Cookies are widely used and help to optimize the pages that you view. By using this site, you agree to their use. more